INNOVADERM CRO IS NOW INDERO.

Atopic Dermatitis (AD) Rescue Case Study

Indero

Indero

Team of Experts

Author picture

Click here for a PDF version of this case study

Outcomes

Indero successfully rescued this AD study and this resulted in:

215% enrollment increase in half the time.​

Dramatic improvement of sites’ engagement.

 

Study Characteristics

  • Study Phase: IIa
  • Patient Population: Atopic Dermatitis
  • IP Route of Administration: Systemic
  • Initial Sites Distribution: 27 in 1 country (US)​
  • Post Rescue Final Sites Distribution: ​30 (kept 15 from the original selection) in 2 continents (Europe and North America)

 

Study Challenges and Solutions

Challenges #1

Patient Recruitment Concerns & Poor Site Management:

  • Enrollment struggles led to trial delays
  • Significant site payment delays and lack of site support and training

Solutions

  • Enhanced outreach and strategic partnerships with additional sites and patients advocacy groups boosted enrollment
  • Manual work done to accelerate payment processes and satisfy sites’ needs

Outcome

  • Recruitment Triumph – Achieved 215% increase in half the time
  • Sites relation – Dramatic improvement with Indero takeover, re-engaging disengaged sites

Challenge #2

Data Oversight Issues:

Significant 6-month data cleaning backlog potentially causing data inaccuracies

Solution

Achieved through rigorous and extensive monitoring, ensuring unparalleled quality

Challenge #3

Missed Deadlines:

Operational inefficiencies derailed the schedule

Solution

Comprehensive restructuration became the trial’s saving grace to improve coordination and adherence to timelines

 

Need help with your next dermatology or rheumatology study? Tell us a little about your needs.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.